Estimating treatment effects in trials with outcome data truncated by death: A case study on aligning estimators with estimands
Clinical Trials · 2025-12 · 22 (6) · 676-686
DOI: 10.1177/17407745251360645 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Trials, online erschienen am 04.10.2025. Verfasst von Tra My Pham und 5 weiteren Autor:innen. Beteiligte Einrichtung: MRC Clinical Trials Unit at UCL, London, UK. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIHR Manchester Biomedical Centre.
Abstract (Originalsprache)
Background/Aims: Randomised clinical trials assessing treatment effects on health outcomes (e.g. quality of life) can be affected by data truncation by death, where some patients die before their outcome measure is assessed and their data become undefined after death. The ICH E9(R1) addendum on estimands discusses four strategies for handling such terminal intercurrent events: hypothetical, composite, while-alive, and principal stratum. While the addendum emphasises the importance of aligning statistical methods of analysis (i.e. estimators) with estimands, it does not provide specific guidance and consideration on the choice of estimators in practice. We aim to (1) demonstrate how some statistical methods commonly used in trials can be used to estimate different intercurrent event strategies for handling data truncation by death; and (2) describe how missing outcome data (e.g. due to missed assessments or loss to follow-up) can be handled for each estimator.
Method
We use data from SCORAD, a non-inferiority randomised trial comparing single-fraction versus multifraction radiotherapy on ambulatory status at 8 weeks (primary outcome) among patients with spinal canal compression from metastatic cancer. Here, we estimate the effect of radiotherapy on quality of life (secondary outcome), quantified by the difference in mean global health status between the two groups at 8 weeks. We outline the strategies for handling death and describe a selection of commonly used estimators corresponding to each strategy. The handling of missing data is considered and demonstrated as part of the estimation process.
Results
The hypothetical strategy, targeting a treatment effect assuming patients had not died, can be estimated using linear mixed models (a likelihood approach) or multiple imputation (a method commonly used for handling missing data). The composite and while-alive strategies relate to the ‘outcome’ attribute of the estimand; the former incorporates death into the definition of the primary outcome, the latter only uses outcome data before death. These can be estimated by re-defining the outcome, for example, assigning a value reflecting poor global health status post-death, or using the last global health status observed before death. The principal stratum strategy, targeting a treatment effect among patients who would not die under either treatment, can be estimated by an analysis of survivors under specific assumptions. Missing data can be handled with linear mixed models or multiple imputation.
Conclusions
Regarding death as an intercurrent event in the process of defining the estimand for the trial will help clarify the choice of suitable estimators. When choosing the estimators, it is important to consider the assumptions required by the estimators as well as their plausibility given the setting of the trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- MRC Clinical Trials Unit at UCL, London, UK.
- Cancer Research UK & UCL Cancer Trials Centre, London, UK.
- Mount Vernon Cancer Centre, Northwood, UK.
- Division of Cancer Sciences, The University of Manchester, Manchester, UK.
ORCID-Profile: Tra My Pham, Brennan C Kahan, Memuna Rashid, Ian R White
Förderung
- Medical Research Council
- NIHR Manchester Biomedical Centre
Zitieren
APA
Pham, T. M., Kahan, B. C., Lopes, A., Rashid, M., Hoskin, P. J., & White, I. R. (2025). Estimating treatment effects in trials with outcome data truncated by death: A case study on aligning estimators with estimands. Clinical Trials, 22(6), 676-686. https://doi.org/10.1177/17407745251360645
Vancouver
Pham TM, Kahan BC, Lopes A, Rashid M, Hoskin PJ, White IR. Estimating treatment effects in trials with outcome data truncated by death: A case study on aligning estimators with estimands. Clinical Trials. 2025;22(6):676-686. doi:10.1177/17407745251360645
BibTeX
@article{Pham2025,
author = {Pham, Tra My and Kahan, Brennan C and Lopes, Andre and Rashid, Memuna and Hoskin, Peter J and White, Ian R},
title = {Estimating treatment effects in trials with outcome data truncated by death: A case study on aligning estimators with estimands},
journal = {Clinical Trials},
year = {2025},
volume = {22},
number = {6},
pages = {676--686},
doi = {10.1177/17407745251360645}
}
EUVIMED